文献速递药物相互作用

卡格列净药物相互作用潜力的体外与基于生理的药代动力学评估

In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin.
PubMed 文献 · Br J Clin Pharmacol · 2016-12-20

本研究通过体外实验和生理药代动力学(PBPK)模型评估卡格列净引起临床药物相互作用(DDI)的可能性。结果显示卡格列净主要经UGT1A9和2B4代谢,是外排转运体底物,体外弱抑制CYP3A4等酶和转运体,但基础模型和PBPK模拟提示与探针底物无临床相关相互作用。结论认为卡格列净既不是临床重要相互作用的肇事者也不是受害者。

要点

  • 卡格列净主要经UGT1A9和2B4代谢,不是OATP、OAT、OCT等摄取转运体底物。
  • 体外弱抑制CYP3A4、2C9、2B6、2C8及P-gp、MRP2,但基础模型预测相互作用风险中至低。
  • PBPK模拟显示与辛伐他汀、S-华法林、安非他酮、瑞格列奈无临床相关相互作用。

核心结论

  • 卡格列净既不是临床重要药物相互作用的肇事者,也不是受害者。

研究设计与样本

  • 采用体外试验系统(含药物代谢酶或转运体)评估卡格列净的DDI潜力,并应用基础预测方法判断体内相互作用可能性。
  • 建立生理药代动力学(PBPK)模型,模拟卡格列净对CYP的抑制可能性及与CYP探针底物的临床DDI。

主要发现

  • 卡格列净主要经尿苷5'-二磷酸-葡萄糖醛酸转移酶1A9和2B4代谢。
  • 卡格列净是外排转运体P-糖蛋白、乳腺癌耐药蛋白和多药耐药相关蛋白-2的底物,但不是OATP1B1、OATP1B3、OAT1、OAT3、OCT1和OCT2的底物。
  • 体外抑制试验中,卡格列净对CYP3A4的IC50为27 μmol/l(SE 4.9),对CYP2C9为80 μmol/l(SE 8.1),对CYP2B6为16 μmol/l(SE 2.1),对CYP2C8为75 μmol/l(SE 6.4),对P-糖蛋白为19.3 μmol/l(SE 7.2),对多药耐药相关蛋白-2为21.5 μmol/l(SE 3.1)。
  • FDA和EMA指南推荐的基础模型预测这些CYP和的外排转运体相互作用可能性为中至低。
  • PBPK DDI模拟卡格列净与CYP探针底物(辛伐他汀、S-华法林、安非他酮、瑞格列奈)未显示人体内相关相互作用,因为合用与不合用卡格列净及其95%CI的探针底物平均AUC和Cmax比值均在0.80-1.25内。

临床怎么用

  • 基于现有体外和PBPK模拟证据,卡格列净与CYP探针底物合用时通常无需调整剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Canagliflozin is a recently approved drug for use in the treatment of type 2 diabetes. The potential for canagliflozin to cause clinical drug-drug interactions (DDIs) was assessed. METHODS: DDI potential of canagliflozin was investigated using in vitro test systems containing drug metabolizing enzymes or transporters. Basic predictive approaches were applied to determine potential interactions in vivo. A physiologically-based pharmacokinetic (PBPK) model was developed and clinical DDI simulations were performed to determine the likelihood of cytochrome P450 (CYP) inhibition by canagliflozin. RESULTS: Canagliflozin was primarily metabolized by uridine 5'-diphospho-glucuronosyltransferase 1A9 and 2B4 enzymes. Canagliflozin was a substrate of efflux transporters (P-glycoprotein, breast cancer resistance protein and multidrug resistance-associated protein-2) but was not a substrate of uptake transporters (organic anion transporter polypeptide isoforms OATP1B1, OATP1B3, organic anion transporters OAT1 and OAT3, and organic cationic transporters OCT1, and OCT2). In inhibition assays, canagliflozin was shown to be a weak in vitro inhibitor (IC50 ) of CYP3A4 (27 μmol l -1 , standard error [SE] 4.9), CYP2C9 (80 μmol l -1 , SE 8.1), CYP2B6 (16 μmol l-1 , SE 2.1), CYP2C8 (75 μmol l -1 , SE 6.4), P-glycoprotein (19.3 μmol l -1 , SE 7.2), and multidrug resistance-associated protein-2 (21.5 μmol l -1 , SE 3.1). Basic models recommended in DDI guidelines (US Food & Drug Administration and European Medicines Agency) predicted moderate to low likelihood of interaction for these CYPs and efflux transporters. PBPK DDI simulations of canagliflozin with CYP probe substrates (simvastatin, S-warfarin, bupropion, repaglinide) did not show relevant interaction in humans since mean areas under the concentration-time curve and maximum plasma concentration ratios for probe substrates with and without canagliflozin and its 95% CIs were within 0.80-1.25. CONCLUSIONS: In vitro DDI followed by a predictive or PBPK approach was applied to determine DDI potential of canagliflozin. Overall, canagliflozin is neither a perpetrator nor a victim of clinically important interactions.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Mamidi RNVS, Dallas S, Sensenhauser C, et al. In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin. Br J Clin Pharmacol. 2016. PMID: 27862160. doi:10.1111/bcp.13186

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。